Elite Pharmaceuticals (OTCMKTS:ELTP) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
This is a summary of recent ratings and recommmendations for Elite Pharmaceuticals and Clearside Biomedical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
0.0% of Elite Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Clearside Biomedical shares are owned by institutional investors. 4.2% of Elite Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Elite Pharmaceuticals and Clearside Biomedical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Elite Pharmaceuticals||$7.57 million||10.42||-$9.28 million||N/A||N/A|
|Clearside Biomedical||$30,000.00||4,100.80||-$82.82 million||($2.69)||-1.03|
Elite Pharmaceuticals has higher revenue and earnings than Clearside Biomedical.
Risk & Volatility
Elite Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
This table compares Elite Pharmaceuticals and Clearside Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Elite Pharmaceuticals beats Clearside Biomedical on 6 of the 11 factors compared between the two stocks.
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products segments. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 15mg and 30mg capsules, and 37.5mg tablets for the treatment of bariatrics under Adipex-P brand name; Lodrane D immediate release capsules for OTC allergy treatment; Methadone HCl 10mg tablets for pains under the Dolophine name; and Hydromorphone HCl 8mg tablets for pains under the Dilaudid name. The company also provides Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril name; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia name; Isradipine 2.5mg and 5mg capsules for cardiovascular diseases; Hydroxyzine HCl 10mg, 25mg, and 50mg tablets for antihistamine treatment under Atarax and Vistaril brand names; Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone name; and Trimipramine Maleate Immediate Release 25mg, 50mg, and 100mg antidepressant capsules under the Surmontil brand, as well as SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; manufacturing and supply agreement with The PharmaNetwork LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA. The company was founded in 1984 and is headquartered in Northvale, New Jersey.
About Clearside Biomedical
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.